Corrigendum to "Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity" [Eur. J. Med. Chem. 55 (2012) 220-227]
Eur J Med Chem. 2018 Jan 1:143:2015.
doi: 10.1016/j.ejmech.2017.10.053.
Epub 2017 Nov 4.
1 Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan; National Center of Excellence for Clinical Trial and Research, National Taiwan University Hospital, Taipei, Taiwan.
2 National Center of Excellence for Clinical Trial and Research, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Molecular Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
3 Institute of Biopharmaceutical Sciences, National Yang-Ming University, Taipei, Taiwan.
4 Biomedical Engineering Research Laboratories, Industrial Technology Research Institute, Hsinchu, Taiwan.
5 Institute of Biopharmaceutical Sciences, National Yang-Ming University, Taipei, Taiwan; Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
6 Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
7 ASAN Institute for Life Science, ASAN Medical Center, Seoul, Republic of Korea.
8 Institute of Biopharmaceutical Sciences, National Yang-Ming University, Taipei, Taiwan. Electronic address: cwshiau@ym.edu.tw.